Adverse Events Sample Clauses
The Adverse Events clause defines the procedures and responsibilities related to the reporting, management, and documentation of any undesirable or unintended medical occurrences during a clinical trial or product use. Typically, this clause outlines the types of events that must be reported, the timelines for notification, and the parties responsible for monitoring and escalating such events. Its core function is to ensure patient safety and regulatory compliance by establishing clear protocols for handling adverse events, thereby minimizing risk and ensuring prompt response to potential safety issues.
POPULAR SAMPLE Copied 3 times
Adverse Events. Subsequent to the date hereof, there shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the New York Stock Exchange, the NASDAQ National Market or the NASDAQ Global Market, (ii) a general moratorium on commercial banking activities in the People’s Republic of China or New York, (iii) the outbreak or escalation of hostilities involving the United States or the People’s Republic of China or the declaration by the United States or the People’s Republic of China of a national emergency or war if the effect of any such event specified in this clause (iii) in your reasonable judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus, or (iv) such a material adverse change in general economic, political, financial or international conditions affecting financial markets in the United States or the People’s Republic of China having a material adverse impact on trading prices of securities in general, as, in your reasonable judgment, makes it impracticable or inadvisable to proceed with the public offering of the Shares or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus.
Adverse Events. The Investigator shall report adverse events and serious adverse events as directed in the Protocol and by applicable laws and regulations. The Investigator shall cooperate with Sponsor in its efforts to follow-up on any adverse events. The Site shall comply with its LEC reporting obligations. Sponsor will promptly report to the Site, the Institution’s LEC, and Quintiles, any finding that could affect the safety of participants or their willingness to continue participation in the Study, influence the conduct of the Study, or alter the Institution’s LEC approval to continue the Study.
Adverse Events. Between the date hereof and each Closing Date, the Company shall not have sustained any loss on account of fire, explosion, flood, accident, calamity or any other cause, of such character as materially adversely affects its business or property considered as an entity, whether or not such loss is covered by insurance.
Adverse Events. The Parties shall co-operate with regard to the reporting and handling of Adverse Events in accordance with the applicable regulatory laws and regulations on pharmacovigilance.
Adverse Events. Institution will ensure, through Principal Investigator, reporting of adverse events experienced by Study Subjects in accordance with instructions in the Protocol and applicable regulations. This includes, where required, prompt reporting by telephone or facsimile to CRO and/or Pfizer. Accordingly, CRO and/or Pfizer will, so far as is lawful, have full responsibility for the reporting of all adverse events to local and international regulatory and/or health authorities. 7.3
Adverse Events. Promptly inform the Bank of the occurrence of any Event of Default or Default, or of any other occurrence which has or could reasonably be expected to have a materially adverse effect upon the Borrower's business, properties, or financial condition or upon the Borrower's ability to comply with its obligations under the Documents.
Adverse Events. Subsequent to the date hereof, there shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the NASDAQ Capital Market, (ii) a general moratorium on commercial banking activities in the State of Florida or United States, (iii) the outbreak or escalation of hostilities involving the United States or the declaration by the United States of a national emergency or war if the effect of any such event specified in this clause (iii) in your reasonable judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Units on the terms and in the manner contemplated in the Prospectus, or (iv) such a material adverse change in general economic, political, financial or international conditions affecting financial markets in the United States having a material adverse impact on trading prices of securities in general, as, in your reasonable judgment, makes it impracticable or inadvisable to proceed with the public offering of the Units or the delivery of the Units on the terms and in the manner contemplated in the Prospectus.
Adverse Events. Pharmacy must report adverse events to the ImmTrac Texas Immunization Registry and Authorizing Physician.15 Pharmacy must also notify the patient’s primary care provider of the administration of
Adverse Events. Pharmacy must report adverse events to the Vaccine Adverse Events Reporting System (VAERS). Pharmacy must also notify the individual’s primary care provider, if an anaphylaxis treatment agent is administered, within ten (10) days of the adverse event.23
Adverse Events. 13 Pharmacy must immediately report adverse events to Authorizing Physician and, if consented to by patient, to the individual’s primary care provider. Pharmacist must report adverse events to the Vaccine Adverse Event Reporting System (VAERS) within seventy-two (72) hours of the adverse event.